Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics posts record 2025 revenue of $3.18 billion, up 11%

Positive Impact 3 of 5 earnings Written later

United Therapeutics reported fourth quarter and full year 2025 results, with full year revenue rising 11% to a record $3.18 billion. Fourth quarter revenue was $790.2 million, up from $735.9 million a year earlier, and diluted earnings per share were $7.70 versus $6.19. The filing shows growth in both the quarter and the year, though it does not include new financial guidance.

Key points

  • Q4 2025 total revenues were $790.2 million, up 7% from $735.9 million in Q4 2024.
  • Full year 2025 net income was $1,334.7 million, or $27.86 per diluted share, compared with $1,195.1 million, or $24.64 per diluted share, in 2024.
  • Tyvaso DPI revenues rose 25% for the full year to $1,292.5 million, while Nebulized Tyvaso revenues were roughly flat at $585.7 million.
  • Cash, cash equivalents, and marketable investments were $4,697.0 million at December 31, 2025.

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECFeb 25, 2026, 6:32 AM ET
Accession number0001082554-26-000007

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.